Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Hematologic Neoplasms 6Leukemia, Myeloid, Acute 3Leukemia 3Invasive Fungal Infections 3Infections 3Mycoses 2Drug-Related Side Effects and Adverse Reactions 2Wilms Tumor 1Testicular Neoplasms 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Neutrophilic, Chronic 1

Interventions

posaconazole 1liposomal amphotericin B 1Voriconazole 1Micafungin 1Fluconazole 1Blood Specimen Collection 1Amphotericin B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Aspergillosis × Voriconazole × Clear all
NCT01207128 2012-04-20

Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis

University of Arkansas

Phase 2 Withdrawn

Aspergillosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡